HOTI is on the move again. After the news ALZM moved from 30 cents to a DOLLAR.
HOTI Acquires a Controlling Interest in Allezoe Medical Holdings (ALZM)
Organ Transport Systems Now Part of Allezoe
BURBANK, CA – March 9, 2011 – Healthcare of Today, Inc. announces that it has obtained a controlling interest in Allezoe Medical Holdings, Inc. (OTCBB: ALZM) (Allezoe). Also as a result of this all-stock transaction, Allezoe acquired Organ Transport Systems, Inc. (OTS) from Healthcare of Today. The acquisition of OTS is the first of several planned acquisitions by Allezoe in the medical device development, manufacturing, and services market.
OTS plans to redefine human donor organ procurement through better preservation, with its LifeCradle® product line. OTS has developed, patented and is in the process of commercializing a portable hypothermic, oxygenated preservation and transport system for human organs. OTS LifeCradle® technology has been developed to provide a safe and cost effective method to transport human organs and improve upon the surprisingly low percentage of donated organs that are actually utilized in transplantation globally.
Largely due to the failures of the current preservation and transport methods and technology, only 27% of donated hearts and only 9% of donated lungs actually can be transplanted. The OTS LifeCradle® technology has already been shown in pre-clinical studies to significantly increase preservation time and improve the condition of transplanted animal hearts compared with systems currently in use. These studies have been presented at national and international professional society conferences and published in major peer-reviewed professional society publications, such as the Journal of Heart & Lung Transplantation.
Michael Holder, President, CEO and Director of OTS, and Hyman White, Secretary, Treasurer and Director of OTS, have been appointed to the Board of Directors of ALZM. Mr. Holder will serve as the CEO of Allezoe and Mr. White as its Secretary and Treasurer. Mr. Holder says, “With the acquisition of Organ Transport by Allezoe Medical, we believe we are positioned to be a biotechnology leader and that our highly skilled leadership and business strategy is suited for introduction to the marketplace. We believe this marriage of opportunity and expertise will prove rewarding for our shareholders as well as the many transplant patients we expect to serve.”
